Skip to contentH
HCW Biologics Inc.
H
HCWBHCW Biologics Inc. Q3 2024 · 10-Q
Revenue$426.42K$426.42K−50.0% vs Q3 2023 Net Income-$3.90M-$3.90MN/M vs Q3 2023 EPS Diluted-$4.13-$4.13N/M vs Q3 2023 Gross Profit$85,285−51.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
HCW Biologics Inc. · CIK 1828673 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,926,471N/M Free Cash Flowderived-$2,963,534N/M Margins · derivedGross margin20.0%−0.5 pt vs Q3 2023
Operating margin-864.1%−268.8 pt vs Q3 2023
Net margin-915.1%−336.2 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 14, 2024 · 45 d after period end